See more : Hensoldt AG (HAG.DE) Income Statement Analysis – Financial Results
Complete financial analysis of MediWound Ltd. (MDWD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MediWound Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Sfinks Polska S.A. (SFS.WA) Income Statement Analysis – Financial Results
- Generation Asia I Acquisition Limited (GAQ-UN) Income Statement Analysis – Financial Results
- C.H. Robinson Worldwide, Inc. (0HQW.L) Income Statement Analysis – Financial Results
- Wellard Limited (WLD.AX) Income Statement Analysis – Financial Results
- PT Unilever Indonesia Tbk (UNLRF) Income Statement Analysis – Financial Results
MediWound Ltd. (MDWD)
About MediWound Ltd.
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18.69M | 26.50M | 23.76M | 21.76M | 31.79M | 3.40M | 2.50M | 1.56M | 601.00K | 259.00K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 15.11M | 13.33M | 14.99M | 14.22M | 11.85M | 2.09M | 1.58M | 2.16M | 2.52M | 2.79M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 3.58M | 13.17M | 8.77M | 7.55M | 19.94M | 1.31M | 918.00K | -600.00K | -1.92M | -2.53M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 19.15% | 49.69% | 36.91% | 34.67% | 62.73% | 38.61% | 36.78% | -38.51% | -319.13% | -975.29% | 0.00% | 0.00% | 0.00% |
| Research & Development | 7.47M | 10.18M | 10.26M | 7.70M | 4.97M | 4.07M | 5.46M | 7.07M | 6.02M | 5.35M | 3.64M | 1.56M | 3.02M |
| General & Administrative | 8.57M | 8.33M | 6.11M | 8.69M | 9.31M | 7.99M | 9.14M | 12.49M | 13.29M | 4.72M | 1.63M | 1.14M | 1.24M |
| Selling & Marketing | 2.80M | 2.04M | 3.39M | 3.23M | 4.06M | 4.19M | 5.36M | 8.40M | 9.28M | 8.83M | 2.26M | 0.00 | 0.00 |
| SG&A | 11.38M | 10.37M | 9.74M | 8.69M | 9.31M | 7.99M | 9.14M | 12.49M | 13.29M | 13.55M | 3.89M | 1.14M | 1.24M |
| Other Expenses | 24.00K | 958.00K | -710.00K | -144.00K | 1.17M | -751.00K | 56.00K | 66.00K | 59.00K | 49.00K | 57.00K | 33.00K | 24.00K |
| Operating Expenses | 18.87M | 21.51M | 19.99M | 16.39M | 15.45M | 5.27M | 14.61M | 19.56M | 19.31M | 18.90M | 7.58M | 2.73M | 4.29M |
| Cost & Expenses | 33.98M | 34.84M | 34.98M | 30.60M | 27.30M | 7.36M | 16.18M | 21.71M | 21.83M | 21.69M | 7.58M | 2.73M | 4.29M |
| Interest Income | 2.34M | 270.00K | 11.00K | 297.00K | 434.00K | 412.00K | 0.00 | 1.27M | 288.00K | 4.67M | 1.00K | 6.00K | 32.00K |
| Interest Expense | 427.00K | 8.92M | 903.00K | 832.00K | 925.00K | 892.00K | 478.00K | 847.00K | 444.00K | 2.11M | 2.44M | 673.00K | 591.00K |
| Depreciation & Amortization | 1.30M | 1.27M | 1.24M | 1.09M | 1.15M | 577.00K | 567.00K | 589.00K | 503.00K | 492.00K | 336.00K | 267.00K | 196.00K |
| EBITDA | -4.89M | -18.09M | -11.22M | -7.75M | 3.42M | -5.09M | -13.12M | -18.30M | -20.72M | -18.33M | -6.50M | 12.25M | -4.10M |
| EBITDA Ratio | -26.19% | -35.22% | -42.01% | -35.61% | 17.75% | -99.47% | -525.64% | -1,255.84% | -3,448.25% | -6,281.85% | 0.00% | 0.00% | 0.00% |
| Operating Income | -15.29M | -8.35M | -11.22M | -8.84M | 4.49M | -3.96M | -13.69M | -20.16M | -21.23M | -21.43M | -7.58M | -2.73M | -4.29M |
| Operating Income Ratio | -81.83% | -31.50% | -47.22% | -40.62% | 14.13% | -116.44% | -548.36% | -1,293.65% | -3,531.95% | -8,272.97% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 8.76M | -11.18M | -2.30M | -436.00K | -2.43M | -1.71M | -846.00K | 1.27M | -444.00K | 2.55M | -920.00K | 14.72M | -532.00K |
| Income Before Tax | -6.53M | -19.52M | -13.52M | -9.28M | 2.07M | -5.67M | -14.53M | -18.89M | -21.67M | -18.88M | -8.50M | 11.99M | -4.82M |
| Income Before Tax Ratio | -34.95% | -73.68% | -56.91% | -42.62% | 6.50% | -166.57% | -582.25% | -1,212.13% | -3,605.82% | -7,287.64% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 185.00K | 78.00K | 27.00K | 325.00K | -1.65M | -9.69M | 8.46M | -1.27M | 861.00K | -2.55M | 7.77M | -13.67M | 1.88M |
| Net Income | -6.72M | -19.60M | -13.55M | -9.60M | 3.72M | -1.06M | -22.15M | -18.89M | -22.09M | -18.88M | -15.35M | 10.94M | -6.17M |
| Net Income Ratio | -35.94% | -73.97% | -57.03% | -44.12% | 11.70% | -31.08% | -887.38% | -1,212.13% | -3,675.21% | -7,287.64% | 0.00% | 0.00% | 0.00% |
| EPS | -0.75 | -3.93 | -3.48 | -2.47 | 0.96 | -0.27 | -6.64 | -6.05 | -7.13 | -6.65 | -5.28 | 3.76 | -2.12 |
| EPS Diluted | -0.75 | -3.93 | -3.48 | -2.47 | 0.96 | -0.27 | -6.64 | -6.05 | -7.13 | -6.65 | -5.28 | 3.76 | -2.12 |
| Weighted Avg Shares Out | 9.01M | 4.99M | 3.89M | 3.89M | 3.88M | 3.87M | 3.33M | 3.12M | 3.10M | 2.84M | 2.91M | 2.91M | 2.91M |
| Weighted Avg Shares Out (Dil) | 9.01M | 4.99M | 3.89M | 3.89M | 3.88M | 3.87M | 3.33M | 3.12M | 3.10M | 2.84M | 2.91M | 2.91M | 2.91M |
MediWound to Participate in Two Upcoming Investor Conferences
YAVNE, Israel, Feb. 05, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced its participation in the upcoming Oppenheimer 34th Annual Life Sciences Conference, taking place...
MediWound (MDWD)'s Technical Outlook is Bright After Key Golden Cross
After reaching an important support level, MediWound Ltd. (MDWD) could be a good stock pick from a technical perspective.
Wall Street Analysts Think MediWound (MDWD) Could Surge 134.77%: Read This Before Placing a Bet
The consensus price target hints at a 134.8% upside potential for MediWound (MDWD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside...
MediWound (MDWD): Strong Industry, Solid Earnings Estimate Revisions
MediWound (MDWD) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns
If approved, NexoBrid will serve as an effective non-surgical treatment for both pediatric and adult burn patients in the U.S.
MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army
Awarded additional $6.7 million to advance NexoBrid as a non-surgical field care solution; R&D project budget increased to $14.4 million Awarded additional $6.7 million to advance NexoBrid as a non-surgical field care solution; R&D project budget increased to $14.4 million
MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads
Results show EscharEx to be safe and effective, and suggest it can go beyond traditional expectations for enzymatic debridement Results show EscharEx to be safe and effective, and suggest it can go beyond traditional expectations for enzymatic debridement
Wall Street Analysts Believe MediWound (MDWD) Could Rally 171.79%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 171.8% in MediWound (MDWD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an...
Does MediWound (MDWD) Have the Potential to Rally 223.05% as Wall Street Analysts Expect?
The consensus price target hints at a 223.1% upside potential for MediWound (MDWD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside...
MediWound Ltd. (MDWD) Q3 2023 Earnings Call Transcript
MediWound Ltd. (NASDAQ:MDWD ) Q3 2023 Earnings Call Transcript November 21, 2023 8:30 AM ET Company Participants Daniel Ferry - LifeSci Advisors Ofer Gonen - Chief Executive Officer Barry Wolfenson - Executive Vice President of Strategy & Corporate Development Hani...
Source: https://incomestatements.info
Category: Stock Reports